---
created: 2025-04-13
updated: 2025-04-13T10:51
id: BfRJ&[!uVS
specialty: "[[neuro]]"
specialty_id: 226
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::08-parkinson-disease-therapy
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::08-parkinson-disease-therapy::carbidopa-levodopa
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::08-parkinson-disease-therapy::mao-inhibitors
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::09-carbidopa-levodopa
  - theme/firstaid::12-neuro-&-special-senses::06-pharm::10-selegiline-rasagiline
  - source/ome-banner
  - theme/sketchypharm::06-neuro/psych::05-antipsychotics-&-parkinsons::03-levodopa/carbidopa,-entacapone,-tolcapone,-selegiline,-ropinirole,-pramipexole,-amantadine
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::neuro::pharmacology
  - theme/b&b::04-neuro::03-movement-disorders::01-parkinson's-disease"
type: flashcard
---

# Question
Dopamine in the CNS may be degraded to **DOPAC** via the enzyme **MAO-B**

---

# Answer
